Join­ing Chang and Bellde­grun, Rafael Ama­do takes a lead­ing R&D post in the next big cell ther­a­py rev­o­lu­tion

Rafael Ama­do spent close to 5 years at Adap­ti­m­mune look­ing to break new ground in the TCR field of on­col­o­gy, go­ing in­side cells to find new tar­gets to com­bat can­cer. As of to­day, he’s mak­ing a switch to the cut­ting edge of one of the hottest fields in cell ther­a­pies, where he’ll be ex­pect­ed to take a lead role on a front-run­ning charge at an off-the-shelf ap­proach in CAR-T.

The Glax­o­SmithK­line vet­er­an — and for­mer head of their on­col­o­gy re­search group — of­fi­cial­ly left Adap­ti­m­mune last week. Now he’s com­ing up on the oth­er side of the week­end as the new head of R&D at Al­lo­gene, run by Kite vets David Chang and Arie Bellde­grun. He’ll start at the be­gin­ning of Sep­tem­ber.

This is the next gen­er­a­tion of en­gi­neered CAR-Ts, de­signed to un­leash a mas­sive im­mune sys­tem at­tack on can­cer that can be cu­ra­tive for many pa­tients. There’s a rapid as­sault at gain­ing the pi­o­neer­ing OK un­der­way. And Ama­do plans to be an im­por­tant part of it.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER